NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT00713427,Study of the WallFlex™ Biliary Partially-covered Stent for the Palliative Treatment of Malignant Bile Duct Obstruction,https://clinicaltrials.gov/study/NCT00713427,,COMPLETED,This is a a prospective study of the WallFlex™ Biliary Partially-covered Stent designed to collect data to support regulatory clearance by the FDA in the United States and to determine the functionality of the WallFlex™ Biliary Partially Covered Stent as a Palliative treatment for malignant bile duct obstruction.,YES,Biliary Strictures Caused by Malignant Neoplasms,DEVICE: WallFlex™ Biliary Partially-Covered Stent,"Number of Participants With Absence of Recurrent Biliary Obstruction, Defined as absence of recurrent biliary obstruction defined as absence of biliary symptoms. Biliary symptoms, included, but were not limited to jaundice, itching, right upper quadrant abdominal pain, nausea, vomiting, fever, and dark urine. Symptom assessment occurred during the Screening/Baseline period and at all follow-up time points., Up to 6 months post treatment or prior to death, whichever came first","Number of Adverse Events Related to the Device and/or Procedure, Number of adverse events (serious and non-serious) related to the device and/or procedure were collected following informed consent, treatment, and at all follow-up timepoints., From time participant signs informed consent until time participant exits study (up to 6 months following stent placement)|Number of Participants With Technical Stent Placement Success, Technical stent placement success defined as the ability to deploy the stent in satisfactory position across the stricture, Initial stent placement procedure|Number of Participants With Occurrence of Re-intervention, A re-intervention is defined as any type of endoscopic, percutaneous, or surgical procedure to improve biliary drainage after insertion of the initial study stent. Re-intervention does not include a second WallFlex stent placement during the 7 days post initial placement as a second stent could have been placed due to misplacement or failure to cover the entire stricture., Up to 6 months post-initial study treatment|Change in Biliary Obstruction Symptoms, Incidence of symptoms of biliary obstruction, up to 6 months post-initial study treatment|Time to Recurrent Biliary Obstruction, Biliary obstruction symptoms were collected at all follow-up visits post treatment and included but not limited to jaundice, itching, right upper quadrant abdominal pain, nausea, vomiting, fever, and dark urine. The time to recurrent biliary obstruction was recorded., Up to 6 months|Change in Bilirubin, Bilirubin change at 1 month following stent placement as assessed against bilirubin at baseline., 1 month following stent placement",,Boston Scientific Corporation,,ALL,"ADULT, OLDER_ADULT",NA,70,INDUSTRY,INTERVENTIONAL,Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT,ENDO-WALLFLEX-BIL-PALL-002|E7020,2007-07,2008-05,2008-05,2008-07-11,2021-05-10,2021-07-30,"ULB Erasme Hospital, Brussels, 1070, Belgium|Hopital Edouard Herriot, Lyon, Cedex 3, 69437, France|EVK Krankenhaus der Universitat Dusseldorf, Dusseldorf, D-40217, Germany|Asian Institute of Gastroenterology, Hyderabaad, 500082, India|Università Cattolica del Sacro Cuore, Rome, 00168, Italy|Academisch Medisch Centrum Universiteit van Amsterdam, Amsterdam, AZ, 1105, Netherlands",
